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Membrane transporters in drug development
The International Transporter Consortium*

Abstract
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Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy
profiles of drugs. This presents several key questions for drug development, including which
transporters are clinically important in drug absorption and disposition, and which in vitro
methods are suitable for studying drug interactions with these transporters. In addition, what
criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if
needed. In this article, we provide the recommendations of the International Transporter
Consortium on these issues, and present decision trees that are intended to help guide clinical
studies on the currently recognized most important drug transporter interactions. The
recommendations are generally intended to support clinical development and filing of a new drug
application. Overall, it is advised that the timing of transporter investigations should be driven by
efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion
criteria), as well as a need for further understanding of the absorption, distribution, metabolism
and excretion properties of the drug molecule, and information required for drug labeling.
Recent progress has been made in understanding the role of membrane transporters in drug
safety and efficacy1. In particular, more than 400 membrane transporters in two major
superfamilies — ATP-binding cassette (ABC; for review see refs 1–5) and solute carrier
(SLC; for review see refs 1,3,6,7) — have been annotated in the human genome. Many of
these transporters have been cloned, characterized and localized to tissues and cellular
membrane domains in the human body. In drug development, particular attention has been
paid to transporters expressed in epithelia of the intestine, liver and kidney, and in the
endothelium of the blood– brain barrier. As a result there is now an enormous body of
literature that focuses on the interaction of drugs and their metabolites with mammalian
transporters present in epithelial and endothelial barriers.

NIH-PA Author Manuscript

Correspondence to Kathleen M. Giacomini, Shiew-Mei Huang and Donald J. Tweedie. K.M.G. is at the Department of Bioengineering
and Therapeutic Sciences, University of California, San Francisco, 513 Parnassus Avenue, California 94143-0912, USA. S.-M.H. is at
the Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993-0002, USA. D.J.T. is at Boehringer Ingelheim
Pharmaceuticals, 900 Ridgebury Road, PO Box 368, Ridgefield, Connecticut 06877, USA. kathy.giacomini@ucsf.edu;
ShiewMei.Huang@fda.hhs; gov; donald.tweedie@boehringer-ingelheim.com.
This report is dedicated to the memory of John M. Strong (1937–2008), Deputy Director of the Laboratory of Clinical Pharmacology,
Center for Drug Evaluation and Research, US Food and Drug Administration (FDA).
*A full list of authors appears in Box 1.
Competing interests statement
The authors declare competing financial interests: see web version for details.
DATABASES
UniProtKB: http://www.uniprot.org
BCRP | MRP2 | OCT1 | OCT2 | OAT1 | OAT3 | OAT4 | OATP1A2 | OATP1A2 | OATP1B1 | OATP1B3 | P-gp
FURTHER INFORMATION
US FDA Guidance, Compliance and Regulatory Information — Clinical Pharmacology:
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm
US FDA Drug Development and Approval Processes —
Drug Development and Drug Interactions:
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm
All links are active in the online PDF

Page 2

NIH-PA Author Manuscript

Numerous studies have suggested that transporters play a part in vivo in drug disposition,
therapeutic efficacy and adverse drug reactions. The in vivo role of transporters is
demonstrated in several animal species, including knockout mice8,9, and by loss-of-function
genetic variants in humans4,10,11. These studies have provided considerable information on
the in vivo role of many ABC and SLC transporters. Clinical pharmacokinetic drug–drug
interaction (DDI) studies have suggested that transporters often work together with drugmetabolizing enzymes (DMEs) in drug absorption and elimination.
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A major goal of preclinical drug evaluation is to propose clinical studies that are needed to
appropriately label a drug for safe and effective use. For example, in vitro studies of drug
interactions with metabolizing enzymes may lead to the design and conduct of DDI studies,
or investigations in individuals with genetic polymorphisms of DMEs12,13. In fact, for drug
interactions with metabolizing enzymes, the US Food and Drug Administration has
developed guidances to assist drug development scientists in conducting informative in vitro
and follow-up clinical studies14,15. By contrast, for drug interactions with transporters,
recommendations about the appropriate conduct of in vitro and in vivo studies are not
generally available, with the exception of drug interactions with multidrug resistance Pglycoprotein (P-gp; also known as MDR1, ABCB1)16. Many questions from pharmaceutical
scientists involved in drug development are now being raised. In particular, which
transporters are clinically important in drug absorption and disposition (distribution and
elimination), and therefore could mediate DDIs? Which methods are suitable for studying in
vitro drug interactions with important transporters? What criteria should be used to trigger
follow-up clinical studies? What follow-up clinical studies should be conducted?
Against this backdrop, we formed the International Transporter Consortium (ITC) (BOX 1)
comprising industrial, regulatory and academic scientists with expertise in drug metabolism,
transport and pharmacokinetics. The ITC met by conference calls between the spring of
2007 and the summer of 2009, and held a workshop in Bethesda, Maryland, USA, in october
2008, which was co-sponsored by the Critical Path Initiative of the US Food and Drug
Administration and by the Drug Information Association. The focus of the workshop was to
identify which transporters, based on current knowledge, are well-established determinants
of pharmacokinetics; discuss methodologies to characterize drug–transporter interactions
using in vitro and in vivo studies; and propose recommendations that are important for drug
development scientists in guiding preclinical and clinical studies of transporter-mediated
drug interactions. For this latter point, the key consideration was that in vitro studies of
drug–transporter interactions, if positive, would lead to, or inform, clinical studies that are
relevant to drug safety or efficacy.
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Here, we present the recommendations of the ITC regarding the conduct of transporter
assays and data interpretation. This manuscript is divided into three major sections. In
Section 1, the key transporters that have a role in drug disposition and response are
described. We focused on transporters that have a compelling body of evidence from
published studies demonstrating a role of the transporter in pharmacokinetics and DDIs.
Many transporters could have been considered in this group; however, after ample
discussions, and realizing that the field is dynamic and will change in the future, the ITC
decided to focus on seven selected transporters for which all members agreed there is
compelling evidence that they are involved in drug absorption, disposition and/or DDIs. In
Section 2, current methods for studying drug–transporter interactions are presented together
with comments about the limitations of each approach. In Section 3, recommendations and
examples of guidelines that should be considered in drug development are presented. The
ITC did not reach consensus on every issue, and in this article we have highlighted areas of
disagreement or in need of further study. Transporter pharmacology is a rapidly emerging
field in drug discovery and development with challenges of overlapping substrate or
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inhibitor specificities across the transporters, and recommendations based on strong
scientific evidence will evolve as new information becomes available.
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Section 1: Overview of transporters
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A limited number of transporters, including several uptake transporters from the SLC
superfamily6 and some ATP-dependent efflux pumps from the ABC superfamily2, have
been given priority in the context of this article. Their selection was based on practical
considerations and on clinical evidence that these transport proteins influence, to different
degrees, drug disposition and/or side effects. FIGURE 1 and TABLES 1,2 describe the
selected transporters as well as other can be explained, in part or in full, by modulation of
important transporters. Note that clinical data documenting the importance of these transport
proteins with respect to drug disposition and/or toxicity continues to emerge. TABLES 1,2
include clinically relevant information with respect to DDIs and genetic polymorphisms.
Examples of clinically relevant DDIs that can be explained, in part or in full, by modulation
of transporter activity are compiled in TABLE 3. Below, we present an overview of P-gp,
breast cancer resistance protein (BCRP; also known as ABCG2); organic cation transporters
(OCTs) and organic anion transporters (OATs); and organic anion transporting polypeptides
(OATPs). For ease of reading we refer to MDR1/P-gp as P-gp throughout this report.
Although evidence is available demonstrating that various members of the multidrug
resistance protein (MRP) and the multidrug and toxin extrusion transporter (MATE) families
are involved in drug disposition, as mentioned in various sections, because of the need to
limit the scope of this manuscript, they are not discussed in detail here. Because of the
extensive body of literature obtained over many years on the interaction of drugs with P-gp,
as well as the vast experience in studying this transporter in the industry, P-gp will be
described in more detail than other transporters. Many issues discussed for P-gp are relevant
for other transporters. In this article capitalized letters are used for human genes and proteins
(for example, SLCO and OATP), whereas only the initial letter is capitalized for rodent
genes and proteins (for example, Abcg2 and Bcrp). The standard human gene nomenclature
is listed in TABLES 1,2, but, in general, the transport proteins or gene products responsible
for transport function are referred to by the names commonly used in the field.
P-glycoprotein
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General description—P-gp mediates the ATP-dependent export of drugs from cells. It is
expressed in the luminal membrane of the small intestine and blood–brain barrier, and in the
apical membranes of excretory cells such as hepatocytes and kidney proximal tubule
epithelia. P-gp has an important role in limiting entry of various drugs into the central
nervous system. In addition, it also plays a part in the intestinal absorption and in the biliary
and urinary excretion of drugs. The level of expression and functionality of P-gp can be
modulated by inhibition and induction, which can affect the pharmacokinetics, efficacy,
safety or tissue levels of P-gp substrates5,17–21.
Substrate and inhibitor selectivity—Initially discovered as a result of its interaction
with multiple anticancer drugs, P-gp is responsible for the efflux across biological
membranes of a broad range of therapeutic drugs. Recently, a high-resolution structure of
the mouse P-gp has been described, which revealed distinct binding sites for drugs22. A
select number of substrates and inhibitors of human P-gp are shown in TABLE 2. P-gp
substrates are generally hydrophobic molecules, of which many are cationic. Multiple
binding sites for substrates and inhibitors on P-gp have been identified using site-directed
mutagenesis23–25.

Nat Rev Drug Discov. Author manuscript; available in PMC 2012 April 13.

Page 4

NIH-PA Author Manuscript

Methodology for evaluating function—Cell lines that express P-gp and inside-out
membrane vesicles prepared from these cell lines can be used to determine whether a drug is
a P-gp substrate or inhibitor. As P-gp is localized in the apical plasma membrane in
polarized cell monolayers, a high efflux ratio of basal-to-apical to apical-to-basal (the so
called B-A/A-B ratio) indicates a potentially significant role for P-gp in transporting drugs
across cell monolayers. A high efflux ratio in vitro has been shown to correlate well with
studies that have demonstrated a role for P-gp in drug penetration to the central nervous
system in mice26,27. By contrast, a high efflux ratio does not always translate into poor oral
absorption. The involvement of P-gp in absorption of a drug is more pronounced if the drug
has a poor apparent permeability coefficient (Papp), or in cases in which there is interplay
between metabolism and efflux.
Mice deficient in Mdr1a or Mdr1a/b are widely used as powerful tools for assessing the role
of P-gp in vivo9. Knockout mice can be used as a reference for complete inhibition of P-gp,
and represent the ‘worst case’ scenario. Sasongko et al.28 demonstrated that the AUCbrain/
AUCblood ratio of 11C-verapamil in humans increased by less than twofold (88 ± 20%) in the
presence of a high intravenous dose of the P-gp inhibitor cyclosporine. By contrast, an
almost eightfold (770%) increase was observed in the Mdr1a/b knockout mice compared
with control mice. These data can be interpreted in multiple ways, but illustrate the
challenge in predicting human transporter-mediated DDIs based on preclinical animal data.
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Clinical significance—The clinical significance of a P-gp inhibitor can be investigated in
humans by assessing the P-gp-mediated clearance or exposure of a probe substrate in the
presence of the inhibitor. Digoxin is transported by P-gp in vitro and should be considered in
DDI studies with new molecular entities (NMEs) that are inhibitors of P-gp (TABLE 3,
BOX 2). Current clinical data indicate that there are no consistent examples in which
inhibition of P-gp in the blood–brain barrier resulted in adverse effects29–31. It is therefore
difficult to extrapolate the data obtained for P-gp inhibitors in knockout mice to humans to
indicate the potential for a clinically significant DDI at the human blood–brain barrier31.
Findings from many studies on the effect of ABCB1 polymorphisms20 on P-gp substrates
have not been consistently reproduced; therefore, routine application of ABCB1
polymorphism analysis to clinical studies is not warranted at this time. Studies with larger
numbers of samples may be needed to clarify the role of ABCB1 polymorphisms in
pharmacokinetics and pharmacodynamics32.
BCRP
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General description—BCRP is a ‘half ABC transporter’ consisting of 655 amino acids
and six transmembrane domains33. BCRP was identified originally as a determinant of
multidrug resistance in cancer cell lines in vitro34,35. BCRP is expressed in the
gastrointestinal tract, liver, kidney, brain endothelium, mammary tissue, testis and placenta.
It has a role in limiting oral bioavailability and transport across the blood–brain barrier,
blood– testis barrier and the maternal–fetal barrier of some selected substrates36,37. The
physiological functions of BCRP include the extrusion of porphyrins from haematopoietic
cells and hepatocytes, as well as the secretion of vitamin B2 (riboflavin) and possibly other
vitamins (such as biotin and vitamin K) into breast milk36.
Substrate and inhibitor selectivity—BCRP actively extrudes a broad range of
endogenous and exogenous substrates across biological membranes37. TABLE 2 lists
selected substrates and inhibitors of human BCRP. High-speed screening and quantitative
structure–activity relationship (QSAR) analysis methods suggest that one amine bonded to
one carbon of a heterocyclic ring is an important component for drug interactions with
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BCRP. In addition, fused heterocyclic ring(s) and two substituents on a carbocyclic ring of
the fused heterocyclic ring(s) are also important chemical moieties for the interaction with
BCRP38–40. Many protein kinase inhibitors such as imatinib (Gleevec; Novartis) carry such
structural components. Substrates of BCRP include pitavastatin (Livalo; Kowa
Pharmaceuticals America)41 and phytoestrogens, such as genistein, daidzein and
coumestrol42.
Methodology for evaluating function—Polarized and non-polarized cell lines
expressing BCRP are used to assay BCRP-mediated transport and inhibition43. In addition,
membrane vesicles containing BCRP that constitutively express the transporter can also be
used43. Prazosin and cimetidine can be used as a positive control in cell lines, whereas
several relatively polar, hydrophilic substrates (for example, methotrexate, oestrone 3sulphate and sulphasalazine) can be used as controls in vesicular transport assays. Since the
initial publications of the Bcrp−/−knockout mouse36,37, drug disposition studies in Abcg2−/−
knockout mice have delineated an important role for intestinal Bcrp as a rate-determining
barrier for the oral bioavailability of several drugs. These include topotecan (hycamtin;
GlaxoSmithKline)44 and sulphasalazine (Salazopyrin; Pharmacia), which had 10-fold to
110-fold increase in relative AUC45. BCRP is also a moderate determinant of the
bioavailability of nitrofurantoin46, some fluoroquinolones47 and imatinib48.
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Clinical significance—Recent clinical studies have demonstrated that subjects with
reduced BCRP expression levels, correlating with the Q141K variant, are at increased risk
for gefitinib (Iressa; AstraZeneca)-induced diarrhoea and altered pharmacokinetics of 9aminocamptothecin, diflomotecan, irinotecan (Camptosar; Pfizer), rosuvastatin (Crestor;
AstraZeneca), sulphasalazine and topotecan49–55. Inter-individual differences in BCRP
function probably contribute to variable bioavailability, exposure (AUC and Cmax), and
pharmacological response of drugs that are BCRP substrates. The most significant clinical
effects are likely to be for drugs that have a low bioavailability and have a narrow
therapeutic index.
OCTs and OATs
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General description—A distinct family of proteins within the SLC superfamily is
encoded by 22 genes of the human SLC22A family, and includes the electrogenic OCTs
(isoforms 1–3) and the oATs (significant isoforms in humans include oAT1–4 and 7, and
URAT1)6,7,56,57. The genes encoding OCT1–3 and OATs encode proteins that are 542–556
amino acids long with 12 predicted transmembrane-spanning domains57. The tissue
distribution and localization of OCTs and OATs are summarized in TABLE 1 and FIG. 1.
There are several published reviews of the molecular characteristics, expression and
function of OCTs7,57–60 and OATs57,61–63.
Substrate and inhibitor selectivity—TABLe 1 summarizes various compounds that
interact with human OCTs and OATs. OCTs transport relatively hydrophilic, low molecular
mass organic cations. Properties of inhibitors of OCT1 and OCT2 have been identified and
include a net positive charge and high lipophilicity59,64. OAT1, OAT3 and OAT4 support
exchange of intracellular 2-oxoglutarate for extracellular substrate62. OAT1 and OAT3
mediate the basolateral entry step in renal secretion of many organic anions, and have
distinct selectivities for different structural classes of type I organic anions. That is,
monovalent (or selected divalent) anions that are less than 500 daltons58; although OAT3
can also transport some positively charged drugs such as cimetidine.
Methodology for evaluating function—In vitro assays that are commonly used to
characterize OCT function include Xenopus laevis oocytes, membrane vesicles and cell lines
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derived from various tissues including proximal tubule (Caki-1), placenta (BeWo) and colon
carcinoma (Caco-2) cells65–69. These are in addition to various human embryonic kidney
(HEK293) cell lines expressing recombinant OCTs68,73,83. Functional assessment of OATs
generally uses heterologous expression in cultured cells or X. laevis oocytes, and such
systems have been used to develop structure–activity relationships for the interaction of
OATs70,71. Studies performed in Oct−/− knockout mice have demonstrated the
pharmacokinetic, pharmacological and physiological relevance of OCTs in organic cation
disposition and activity8,72–74. Studies using Oat1−/− and Oat3−/− knockout mice have also
allowed an initial assessment of the influence of each transporter on the renal handling of
selected compounds, and have led to the identification of endogenous OAT substrates75,76.
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Clinical significance—Recent studies suggest that genetic variation in OCT1 may be a
significant determinant of inter-individual variability in the disposition and response to
cationic drug substrates, particularly metformin73,77. However, such studies have been
controversial78. Recent studies suggest that the activity of OCT1 is positively associated
with the degree to which patients with chronic myeloid leukaemia respond to imatinib79,80.
In Chinese and Korean populations, a common OCT2 variant (A270S) has been associated
with a significant reduction in renal clearance of metformin81,82, but the effect of this
variant may differ depending on the ethnic group83. By contrast, genetic variants in the
OATs have not been associated with changes in drug disposition. DDIs with the OATs and
the OCTs can occur, and may result in reduced renal clearance (TABLE 3). Creatinine,
which is often used to assess filtration clearance, undergoes renal tubular secretion, which
could be inhibited by inhibitors of OCT2. Therefore, other methods should be used to assess
filtration clearance of NMEs in DDI studies involving OCT2 inhibitors. DDIs involving the
OATs and the OCTs are discussed in more detail in Section 3.
OATPs
General description—The OATPs (SLCOs) represent a superfamily of important
membrane transport proteins that mediate the sodium-independent transport of a diverse
range of amphiphilic organic compounds. These include bile acids, steroid conjugates,
thyroid hormones, anionic peptides, numerous drugs and other xenobiotic substances84
(TABLE 1). The general predicted OATP structure consists of proteins with 12
transmembrane domains85. The mechanism of transport appears to consist of anion
exchange by coupling the cellular uptake of substrate with the efflux of endogenous
intracellular substances such as bicarbonate in a process that seems to be electroneutral85–87.
OATP1B1 was cloned by several groups88–91 and its localization along with other OATPs is
shown in FIG. 1. Interestingly, OATP family members are poorly conserved evolutionarily
and orthologues for human oATPs may not exist in rodents.
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Substrate and inhibitor selectivity—OATP1B1 transports a broad range of compounds
such as bile acids; sulphate and glucuronate conjugates; thyroid hormones; peptides; and
drugs such as methotrexate and HMG-CoA reductase inhibitors (TABLE 1). Similar to
OATP1B1, OATP1B3 also transports bile acids; monoglucuronosyl bilirubin;
bromosulphophthalein; steroid conjugates; peptide deltorphin II92; the hepatotoxic cyclic
peptide the thyroid hormones T3 and T4; leukotriene C4; and amanitin; and the cardiac
glycosides digoxin and ouadrugs such as methotrexate and rifampicin86–91. However,
bain92. It is also involved in the uptake of the angiotensin OATP1B3 also exhibits unique
transport properties in II receptor antagonist telmisartan and its glucuronide that it is able to
mediate the cellular uptake of the opioid conjugate91, and the selective uptake of the
intestinal peptide cholecystokinin 8 (refs 93,94). TABLE 1 lists additional details on the
substrate specificity of OATP1B3, and the specificities of OATP1A2 and OATP2B1 are
also noted.
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Methodology for evaluating function—In vitro assessment of OATP transporter
function has relied on a number of transient and stable heterologous expression systems84.
These include X. laevis oocytes, recombinant virus, or stable cell lines expressing an
individual or multiple transporters95. In addition, stable expression of OATP transporters in
polarized cells such as MDCK-II has been reported, typically in combination with efflux
transporters such as MRP2 (refs 96,97). Isolated hepatocytes with OATP inhibitors can also
be used to study OATP transport98,99. More recently, in vivo drug disposition profiles from
Oatp1b2−/− knockout mouse models have been reported100,101 and may reflect, in part, the
activity of both human OATP1B1 and OATP1B3. Additional studies are needed to more
fully validate the utility of rodent models to predict human OATP-mediated drug
disposition.
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Clinical significance—The clinical relevance and DDIs related to OATPs (TABLe 3)
have been noted only for certain OATPs; for example, OATP1B1 and OATP1B3 expressed
primarily in the liver. DDIs involving the OATPs have focused primarily on OATP1B1.
Inhibition of OATP1B1-mediated hepatic uptake appears to contribute to the significant
increase in statin (for example, rosuvastatin) concentrations in blood after cyclosporine
administration102,103 (TABLE 3). Because cyclosporine is an inhibitor of multiple
transporters, the specific transporter involved in the clinical DDI cannot be ascertained;
although OATP1B1 is a likely candidate. In addition, a series of functional polymorphisms
of OATP1B1 have been characterized88. The frequencies of the SLCO1B1 388G allele in
Caucasians, African Americans, and Asians is approximately 40%, 75% and 60%,
respectively88,104–106. Another common single nucleotide polymorphism is 521T>C in
codon 174, which has frequencies of approximately 15%, 2% and 15% in Caucasians,
African Americans, and Asians, respectively88,104–106. The c.388G allele often occurs in a
haplotype with the c.521C allele. These haplotypes — c.388G-c521T (*1B), c.388A-c.521C
(*5) and c.388G-c.521C (*15) — have different activities and also occur at different
frequencies in various ethnic groups. In addition, the promoter variants (−11187G>A and
−10499A>C) may be in linkage disequilibrium with common coding region single
nucleotide polymorphisms104.
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Pharmacokinetic studies indicate that individuals with the SLCO1B1*5 or *15 haplotypes
have increased exposure to statin drugs such as pravastatin106, pitavastatin107, simvastatin
acid108, atorvastatin109 and rosuvastatin110. They also have increased exposure to other
drugs such as repaglinide111, atrasentan112, irinotecan113 and ezetimibe (Zetia; Merck/
Schering–Plough)114. The *5 haplotype is rare (with a frequency of 2% in Caucasians and is
absent in individuals of other ancestries), whereas the *15 haplotype is more common (16%
in Caucasians, 2% in sub-Saharan Africans and 9–12% in Asians)104. However, because of
the large number of patients on statins, even less common variants may have an effect in
many individuals. Compelling clinical evidence supporting an important role for SLCO1B1
polymorphisms has come from a genome-wide association study of simvastatin-induced
myopathy115.

Section 2: Methods for studying transporters
The sections below provide, in order of increasing complexity, assay systems that are
currently available for measuring transporter activity. Although application of these systems
is less labor intensive when radiolabelled or fluorescent substrates are available, the use of
sensitive liquid chromatography–mass spectrometry methodology has provided alternative
high-throughput detection methods116.
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ATPase assay—Substrate-dependent ATP hydrolysis has been used to evaluate the
interactions of substrates and inhibitors with some ABC transporters by colorimetric
analysis of inorganic phosphate release during the transport process. The simplicity of this
assay makes it a practical technique, which can be used in high-throughput assays to screen
for compounds that interact with some ABC transporters117. Drawbacks of this technique
include inconsistency between ATPase activity and the transport rate of some substrates and
inhibitors; a high incidence of false positives and negatives; and the requirement of high
substrate concentrations.
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Membrane vesicle transport assay—Inverted plasma membrane vesicles have been
used primarily to study efflux transporter activity, in particular for ABC transporters118. A
wide variety of cell lines have been used to prepare membrane vesicles, such as drugselected cells, transfected cells and baculovirus-infected insect cells. Assay mixtures should
contain an ATP-regenerating system to maintain constant ATP concentrations during the
assay period; a blank in which ATP is replaced by 5′-AMP is recommended. A major
advantage of this methodology is that drugs are directly applied to the cytoplasmic
compartment and influx, rather than efflux, is measured. This enables detailed kinetic and
QSAR analyses for substrate or inhibitor interaction with the target transporter40.
Determining the uptake or efflux of the hydrophobic compounds may be problematic
because of the high degree of background binding to cell membranes in vesicle or cellular
systems. Vesicle transport assays with hydrophobic compounds may require different sizeexclusion techniques116–118.
Cell-based assay systems
Cell-based assay systems can be used in drug discovery to identify substrates and inhibitors
for individual transporters and for developing QSAR models. In addition, these systems can
be used for mechanistic studies to assess transport mechanisms, the rate-limiting step in
trans-epithelial transport, and transporter-based DDIs.
Data from multiple experimental systems are often useful in confirming the involvement of
a transporter with a potential substrate. Various cell-based assay systems are described
below.
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Polarized cell lines without recombinant transporters—Vectorial transport systems
in which flux can be measured in two directions (namely, apical-to-basolateral and vice
versa) are standard methods for evaluating drug transport across the small intestine and the
blood–brain barrier. However these systems have some limitations. For example, Caco-2
cells can vary in their transporter expression profiles compared with the small intestine;
although some data support strong correlation with human jejunum119. Although
endogenous expression levels of transporters may be low in MDCK and LLC-PK1 cell lines,
these have similar limitations. Immortalized human kidney cells (for example, Caki, IHKE-1
and NRK52E) can be used to understand regulation of key drug transport processes;
although limitations include their inability to replicate transport processes present in the
intact kidney120. Recently, chemically synthesized RNA interference molecules have been
used to silence expression of various genes in mammalian cell lines. By selectively
knocking down endogenous transporters, the new cell lines could be used to study the role
of a particular transporter in the transport of drugs121–123.
Single- and double-transfected cell lines: Recombinant transporters that are stably or
transiently expressed in various cell lines can be used to characterize drug transporter
interactions. Cell-based assay systems for quantitative drug transport studies include cell

Nat Rev Drug Discov. Author manuscript; available in PMC 2012 April 13.

Page 9

NIH-PA Author Manuscript

lines expressing uptake or efflux transporters, or both123,124. Cultured cell lines used to
study drug transporter interactions include cell monolayers such as MDCK, LLC-PK1,
hEK293 or Cho cells grown on solid support. Such monolayers can be used to assess uptake
and efflux by single recombinant transporters, or by multiple recombinant transporters, and
kinetic measurements can be obtained. Various ABC transporters have been analysed in
monolayers of polarized cells, such as MDR1-transfected MDCK II cells, by measuring BA/A-B flux ratios of compounds. Apart from single-transfected cell lines, polarized cells
that stably express multiple transporters — for example, a recombinant uptake transporter in
their basolateral membrane and an efflux transporter in their apical membrane — have been
developed97,124–127. These cell lines may overcome the limitation of certain singletransfected cells that often lack the endogenous uptake or efflux transporters to provide a
complete mechanism for trans-cellular transport of a molecular entity. It is noted that
compounds may undergo uptake or efflux by multiple transporters in intact organs, and
therefore even double-transfected cell lines may not predict the true in vivo situation128.
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Primary cells: Primary-cell-based assays are derived from intact tissue, which, at the time
of isolation, express the full complement of drug transporters present in a given tissue or
cell. Thus, human primary cells may be used to study drug disposition and clinically
relevant drug interactions. However, these cells can adapt to culture conditions over time,
requiring strict definition of culture methods to ensure proper polarization, expression and
localization of drug transporters. For example, brain microvessel endothelial cells require
monitoring of tight junction integrity, and renal proximal tubule cell usage is limited by
tubule collapse in culture. In addition, investigation of intestinal drug transport in isolated
intestinal cells or shed enterocytes is limited by their inability to form well-defined
monolayers in culture.
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Sandwich-cultured primary hepatocytes: Suspended primary hepatocytes have been
shown to reproduce hepatic uptake function129. Unfortunately, the in vivo polarity of
hepatocytes is rapidly lost upon isolation, leading to the inability to assess the potential for
canalicular efflux. This polarity can be regenerated when hepatocytes are cultured in a
sandwich configuration between two layers of gelled collagen130,131. The drug-metabolizing
capabilities and the regulatory machinery of hepatocytes are retained, as well as expression,
localization and function of various hepatic transport proteins in the sinusoidal and
canalicular membranes132. Utilizing sandwich-cultured rat and human hepatocytes, good
correlations have been demonstrated between in vitro and in vivo biliary clearance for some
compounds133. This system can provide an estimate of intracellular drug and/or metabolite
concentrations. A caveat of the sandwich-cultured hepatocyte model is that it is not as
simple to establish as primary cells, and the nature of the culture system does not allow for
considerations of other factors that would influence uptake and efflux of compounds (for
example, loss of sinusoidal flow or lack of exteriorized bile flow).
Considerations for use of in vitro systems in evaluating transporter interactions: In
vitro technologies for determining the interaction of drugs with transporter proteins are
described here and in the literature (see sections above). These techniques and tools
continually evolve, and so prescriptive approaches in an article such as this are at risk of
being out of date in the near future. The ideal experimental approach considers many factors
such as stage of development (discovery versus clinical phases); physicochemical properties
of the NME; and the required outputs from an investigation (for example, efflux ratio,
kinetic parameters Km and Vmax, and uptake clearance). Whatever the selected experimental
approach, it is essential that the system be well characterized with known substrates or
inhibitors, and that appropriate controls are incorporated to verify test results. Due
consideration should be given to the choice of concentrations; time points (for example,
within linear ranges, giving appropriate signal-to-noise ratio); calculation methods
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appropriate to the test system; and justification that the probe substrates or inhibitors allow
tangible extrapolation to the clinical situation.
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Intact organ/in vivo models
Numerous transporter-gene knockout and naturally-occurring transporter-deficient animal
models have been characterized in recent years, and their commercial availability has been
increasing steadily134. Knockout models have illustrated the role of transporters in
physiology, protection of major blood–tissue barriers, and the absorption and excretion of
xenobiotics and endogenous compounds. For instance, although the localization of P-gp in
the blood–brain barrier has been known, its profound role in limiting brain exposure of some
xenobiotics became apparent only after demonstrating that Mdr1a−/− mice displayed a 100fold higher sensitivity towards ivermectin135. And although a key role for BCRP in
protecting the blood–brain barrier remains to be demonstrated, recent evidence obtained in
Bcrp−/−/Mdr1a−/−/Mdr1b−/− triple-knockout mice treated with lapatinib (Tykerb/Tyverb;
GlaxoSmithKline) suggested that Bcrp and P-gp may have a combined effect at the blood–
brain barrier136.
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Numerous transporters have been implicated in the clearance of various drugs and
metabolites. The importance of a transporter-based elimination pathway is determined by
the fraction of total clearance mediated by the transporter. Appreciable alterations (greater
than twofold) in exposure occur only when a major elimination transport pathway is
inactivated or extensively inhibited (that is, unbound inhibitor concentration [I]/Ki ≫ 1, in
which [I]/Ki is the concentration of inhibitor relative to its inhibition constant)137.
Transporter knockout models are useful in establishing the extent of the contribution of the
ablated pathway to overall clearance in that species.
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Species, strain, sex, diet and housing condition differences, as well as compensatory
mechanisms, are a limitation of knockout and mutant models. All these variables should be
considered carefully in the interpretation of data, and in attempts to extrapolate findings
across species. For example, hepatic Mrp2 expression in rats is approximately tenfold higher
than in humans138, and species differences in substrate specificities have been observed139.
Therefore, the relevance of biliary excretion via Mrp2 in rats compared to other species
should be confirmed further with, for example, knockout mice and in vitro
systems138,140,141. Gender differences in the expression of certain transporters may exist;
higher hepatic BCRP expression in males has been established in both mice and humans142.
Strain differences have also been reported. For example, hepatic Mrp4 is upregulated only in
certain Mrp2−/− mouse strains143,144. Direct translation of preclinical transport findings to
the clinic is challenging because of species differences in transporter expression, substrate
affinity, physiological function and interplay between transporters and enzymes. humanized
transporter animal models145 and stem cells are promising tools that may prove to be useful
in the near future to study the absorption, distribution, metabolism and excretion (ADME)
properties of compounds.
Contribution of transporters in vivo
Estimating the contribution of transporters to total tissue uptake and excretion is necessary
for understanding their importance in drug disposition. This estimate allows the prediction
of the extent to which inhibition of, or a genetic polymorphism in, a particular transporter,
will affect drug concentrations in plasma and tissues. Unfortunately, unlike cytochrome
P450 (CYP) enzymes, selective inhibitors or antibodies for most drug transporters have not
been identified; although some progress has been made. For instance, potent inhibitors for
BCRP and P-gp have been described2. The relative contribution of OATP1B1 and
OATP1B3 can be estimated in human hepatocytes by measuring the proportion of uptake of
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test compounds that is inhibited by oestrone-3-sulphate, which is an OATP1B1 inhibitor146.
A method using reference compounds (substrates) for specific liver uptake transporters also
has been proposed (for example, cholecystokinin 8 for OATP1B3)147,148. The reference
compound should be a specific substrate for a particular transporter. The contribution of a
specific transporter to the uptake of the test compound in human hepatocytes can be
calculated by taking the ratio of the uptake of the reference compound in human hepatocytes
to the uptake in cells transfected with the specific transporter (relative activity factor) and
multiplying that ratio by the uptake of the test compound in the transporter-expressing cells.
Unfortunately, for most transporters, reference compounds are not yet available. Instead of
relative activity factor values, the ratio of the expression level of a specific transporter in
human hepatocytes to that in transporter-expressing cells estimated by the band density of
Western blot analysis of cell-surface protein can also be used148.
The relative importance of uptake and efflux transporters in the pharmacokinetics of drugs
in vivo in humans can be quantitatively estimated by using physiologically-based
pharmacokinetic (PBPK) modeling. For example, the effects of changes in OATP1B1 and
MRP2 activity on systemic and hepatic exposure of pravastatin were simulated using a
PBPK model incorporating blood, liver (the clearance and pharmacological target organ),
and peripheral organs149. Application of this modeling approach to other drugs has
demonstrated its broader validity150,151.
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Imaging techniques can qualitatively and quantitatively elucidate the role of transport
proteins in drug disposition (for example, whole body autoradiography and positron
emission tomography (PET)). PET is a noninvasive imaging method that is useful for
accurately measuring pharmacodynamic end points in humans and preclinical species.
Examples of end points include the level of dopamine D2 receptor occupancy of
antipsychotics in the brain152, or the amount of tracer accumulation (for example,11C,13N
or18F) in an organ over time to quantify transporter activity. [11C]-N-Acetyl-leukotriene E4
has been used to study hepatobiliary elimination in normal animals, including monkeys, and
in Mrp2-deficient mutant rats153. [11C]-verapamil was used to measure the effect of
inhibition of P-gp activity in the blood–brain barrier28,152,154. PET probes are currently
being developed for defined transporters; however, to use these probes a cyclotron must be
in close proximity owing to the short half-lives of some PET tracers, such as [11C]-labelled
compounds.
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Gamma scintigraphy is a non-invasive imaging method utilizing short-lived gamma-emitting
radioisotopes (for example, 99mTc) that can be used to quantify transporter activity and
modulation. However, available probes have not been characterized completely for specific
transporters. 99mTc-sestamibi has been used to assess MDR1 P-gp activity155,156,
while 99mTc-mebrofenin and analogues have been used to measure MRP2 function157–159.
Gamma scintigraphy has been used to directly quantify biliary and intestinal drug clearance
in humans160,161. Use of 99mTc probes to assess hepatic transport function in patients
receiving irinotecan162 and vinorelbine163 provides interesting translational applications for
gamma scintigraphy and the possibility to individualize drug dosage regimens. But, practical
reasons may limit the application of imaging methods in the later phases of drug
development.
Interplay of efflux transporters and enzymes
The considerable overlap in the substrate specificity and tissue localization of CYP3A and
P-gp has led to the hypothesis that this enzyme and transporter pair act as a coordinated
absorption barrier against xenobiotics164,165. Clinical studies investigating the importance of
intestinal CYP3A and P-gp through inhibition or induction of these proteins have
demonstrated that the role of P-gp in the intestine extends beyond simply limiting absorption
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of the parent drug164,166,167. P-gp also increases the access of drug for metabolism by
CYP3A through repeated cycles of absorption and efflux. That is, after penetration into
enterocytes, molecules that escape metabolism are eliminated from the cells via P-gp or
other apical ABC transporters but then re-enter the enterocytes168,169. It has been shown that
the residence time of the drug in the intestine is prolonged with the aid of P-gp, thereby
increasing the chance of local metabolic conversion by CYP3A4 (refs 168,169).
Transporters and enzymes in drug clearance
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Drug uptake followed by metabolism and excretion in hepatocytes and kidney proximal
tubule epithelia is a major determinant of the systemic clearance and exposure of many
drugs. Vectorial transport of anionic drugs (for example, statins and angiotensin-converting
enzyme inhibitors) from the blood to the bile or urine via an uptake and efflux transporter is
important for determining drug exposure in the circulating blood and in organs. Sugiyama
and co-workers170,171 have characterized the interplay of enzymes and transporters to
understand the importance of parameters that determine the intrinsic unbound drug clearance
in the intestine, liver and kidney. For highly permeable drugs172–174 in which neither active
uptake nor efflux is rate-limiting, the traditional organ clearance models incorporating blood
flow, extent of protein binding, and intrinsic metabolic and excretion clearance may hold.
However, most anionic drugs and some hydrophilic organic cationic and zwitterionic drugs
exhibit poor membrane permeability172–174. These types of drugs require transporters for
their efficient penetration into or out of the liver or kidney. In such cases, the intrinsic organ
clearance is a hybrid of three parameters: the intrinsic clearances for cellular uptake and
efflux into the systemic circulation; the traditional organ intrinsic clearance, representing
metabolism; and biliary and renal excretion. Each of these uptake, metabolic or efflux
clearances can be rate-determining for certain drugs175. Therefore, the effects of changes in
metabolism and transport activity resulting from interactions with co-administered drugs, or
polymorphisms, should be considered in predicting potential changes in the systemic
exposure of drugs. Modeling systemic exposure changes for some drugs can be done with
PBPK modelling as described in the section above, thus providing initial predictions of drug
interaction potential. The role of transporters, including transporter–enzyme interplay, in the
pharmacokinetics of orally administered drugs has been reviewed recently176.
Computational models
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The application of computational modeling algorithms to gain insight into transporter–
substrate interactions has met with increasing success by the availability of high-quality data
sets and atomic resolution structures of several major facilitator proteins. This burgeoning
field can be divided broadly into indirect ligand-based techniques, such as pharmacophore
and 3D-QSAR modeling, and direct structure-based approaches, such as homology or
comparative modeling based on available crystallographic data177 (FIG. 2). However,
synergistic models fusing both techniques are becoming increasingly important178. Ligandbased models describe a protein’s structural requirements for substrate or inhibitor
interaction by correlating the molecular features of validated substrates or inhibitors with
their biological activity38–40,64,178–180. Most models are limited to predicting putative
inhibitors; although some models predict substrates. However, such models generally do not
robustly predict the rate of substrate transport177,178,181. Pharmacophore models can be used
successfully to screen large databases and identify novel transporter ligands. Structure-based
approaches generate three-dimensional models of a target transporter based on the structure
of an appropriate scaffold protein; currently available structures include bacterial solute
transporters and an ABC transporter (Sav1866). A unique challenge in modeling membrane
transporters concerns the generation of robust models using low levels of sequence identity
and divergent membrane topologies. Ultimately, the docking of ligands may guide ligandbased and rational drug design as well as allow for screening of large databases.
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The identification of membrane transporters that influence the disposition and safety of
drugs is a new challenge for drug development programmes, as well as for regulatory
agencies worldwide. Drug transporter information is becoming common in drug labels, and
provides important mechanistic ADME information that is useful for patients, physicians,
regulatory agencies and research scientists. For instance, the label for mycophenolate
mofetil highlights the role of MRP2 in the hepatic disposition of mycophenolic acid; the
atorvastatin label indicates the role of oATP1B1; and the varenicline label discusses the
involvement of oCT2 in its interaction with other drugs. other examples include the
sitagliptin (Januvia; Merck) label, which has information about the role of P-gp and oAT3 in
the drug’s clearance; the cidofovir label, which includes information on the potential
modulation of renal toxicity by coadministration of an OAT inhibitor, probenecid; and the
lapatinib label, which includes information on P-gp, BCRP and OATPs182. Transporter
substrate or inhibition studies should be undertaken specifically to clarify the impact
transporters have on a drug’s disposition, efficacy and safety, including their importance in
DDIs. Thus, the ability to move a test compound rapidly into the clinic and to plan
effectively for its clinical development will, in part, depend on preclinical assessments of the
interaction of drug candidates with transporters.
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The ITC discussed the characteristics of an NME that would trigger an in vitro interaction
study with a specific transporter. An understanding of the physicochemical properties of the
drug (for example, molecular mass, charge and lipophilicity) and the organ(s) involved in
clearance of the NME will help determine which transporter–NME interactions should be
studied in vitro. For example, an NME that is cleared exclusively by the kidneys should not
(initially) be evaluated as a substrate for the hepatic transporter OATP1B1. Furthermore,
consideration of the physicochemical and pharmacokinetic properties of an NME is also
important in assessing the likelihood of a clinical DDI. For example, the solubility,
permeability and degree of metabolism of an NME will affect its likelihood for a DDI with a
P-gp or BCRP inhibitor (BOX 2).
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Of the numerous drug transporters identified so far, P-gp, BCRP, OATPs, OCTs and OATs
have been implicated (and studied) most frequently in clinical practice. As outlined in
Section 2, various in silico, in vitro and in vivo tools are available to evaluate the role of
transporters in the disposition of a drug. Examples of potential decision trees for these
clinically relevant transporters are included here (BOXES 2–6), and are intended to provide
guidance to sponsors and regulatory agencies as to when to conduct clinical studies to
investigate the importance of transporters in a drug’s disposition. The recommendations
proposed herein are generally intended to support clinical development and filing of a new
drug application. Case studies of decision analyses are provided in BOX 7. The timing of
transporter investigations should be driven by efficacy; safety; clinical trial enrolment
questions (for example, exclusion and inclusion criteria); the need to further understand the
ADME properties of the drug molecule; and transporter information needed for drug
labeling. The proposed decision trees represent starting points for discussion. The US Food
and Drug Administration draft Drug Interaction Guidance14,15,183is recommended for use in
conjunction with this report as a starting point to develop a strategy for addressing
transporter issues during drug development.
The lack of specific inhibitors and substrates for transporters is well recognized, and
represents an area of research that warrants further research. However, this should not be
seen as a reason not to move forward with a clinical (or preclinical) drug interaction study,
as the primary reason for conducting a drug interaction study is to provide information for
dose adjustments. Even though it is desirable to understand the mechanisms responsible for
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DDIs, elucidating the mechanisms is not the primary objective of clinical DDI studies;
understanding the required dose adjustments for patients is the single most important
objective. The supporting preclinical and in vitro transporter data are essential in the design
of the clinical DDI study.
Summary and conclusions
The focus of the ITC has been to provide, where possible, consensus on the current
knowledge of transporters in drug development. The ITC identified areas in which there was
agreement on the current status of the field, existing challenges and future directions.
Importantly, the ITC has provided some guidelines that industry and regulatory agencies can
apply to assist in the development of safe and effective medications (see decision trees in
Section 3). Although this topic has been addressed to some extent previously184, the field of
drug transporters is rapidly advancing. Consideration must be given to the role of
transporters in the absorption (for example, intestinal P-gp and BCRP); distribution (for
example, P-gp at the blood–brain barrier, and OATP1B1, OATP1B3 and OATP2B1 for
hepatocyte uptake); and excretion (for example, OATs and OCTs for renal elimination) of
NMEs in development. One could also argue that metabolism should be included to
complete the ADME paradigm, as intracellular drug concentrations can be affected by an
interplay between transporters and DMEs, as summarized in Section 2 (refs 166,169).
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There are significant challenges that result from these rapid developments. Our applied
knowledge of DMEs progressed through the 1990s and was successfully practiced to
address specific issues in the pharmaceutical industry. A comparison between the
experiences with DMEs and the current challenges with transporters is inevitable, and can
also be informative. Will successes in the transporter field parallel the successes in the field
of DMEs? And will the fields be integrated to provide a more holistic approach to clinical
trials of NMEs? Overall, from a mechanistic perspective, transporters offer complexities that
are distinct from those of DMEs. Typically, tissue-specific drug concentrations are
determined by both uptake and efflux transporters within a tissue. Drug concentrations
measured in plasma, therefore, may not reflect levels in organs such as liver and brain; this
important concept has been illustrated in studies with transporter-knockout mice.
Furthermore, in contrast to DMEs, which are largely concentrated in the liver and intestine,
transporters are present in varying abundance in all tissues in the body, and have important
roles in drug distribution and tissue-specific drug targeting, as well as in drug absorption and
elimination. Another complexity of drug transporters, which is also seen for DMEs, is the
issue of redundant specificities among transporters within a particular tissue. For example,
in a given tissue, there may be redundant influx and efflux transporters such that multiple
transporters with overlapping substrate specificities will determine tissue-specific drug
concentrations. Standardized, well-characterized, generally accessible in vitro assay systems
are needed to define the roles of the different transporters in drug absorption, distribution
and elimination. These are in addition to clinically relevant, selective probe substrates,
inhibitors and tracers suitable for imaging studies. The Critical Path Initiative has
highlighted the enormous need for modern tools for use in drug development185. In this
manuscript, we have suggested models for decision trees that can be used in the
development of drugs. Much time was spent by the ITC in discussing whether to include
such decision trees here. Many expressed concerns that decision trees could and would be
rigidly interpreted as the sole path for in vitro and in vivo testing of transporter–drug
interactions. Importantly, there was concern that the field was not sufficiently advanced, and
that there are gaps in our knowledge of the in vivo role that transporters play in drug
absorption and disposition in humans. Moreover, tools such as selective probes and
inhibitors were not available at this time. However, others felt that the field was evolving
and that decision trees, interpreted with flexibility, might be useful in the development of
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drugs and the collection of data to refine the decision trees. All felt that Considerable
caution must be exercised in the use and interpretation of the decision trees presented here,
and all acknowledged that the decision trees will need to be modified regularly as the field
of transporter pharmacology grows. At some point in the future, integrated transporter and
enzyme decision trees should be considered. The proposed decision trees attempt to define
what can be extrapolated from current knowledge to aid in guiding the need, or lack thereof,
for clinical studies. The decision trees that were constructed included conservative criteria
for each decision so as to reduce false negatives. However, concern was expressed that an
abundance of false positives will have a detrimental effect on the development of new drugs.
Thus, a balance in the decision trees is clearly needed. The evolution and appropriate
application of these decision trees will require constant monitoring. How can this be
achieved with an assured and encompassing measure of success? Constant questioning of
current practices with ongoing dialogue between academic institutions, regulatory agencies
and industry will ensure the development of safe drugs.
Box 1 | The International Transporter Consortium
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The International Transporter Consortium considers this report as a work in progress, and
is highly interested in obtaining feedback. Please send any comments, including areas
that have not been included in this report but should be considered in the next version as
well as controversial concepts, to the corresponding authors (highlighted by asterisk).

Box 2 | Decision trees for P-lycoprotein or BCRP substrate interactions
Although the current US Food and Drug Administration draft Drug Interaction Guidance
provides a decision tree specifically for P-glycoprotein (P-gp; also known as MDR1,
ABCB1)14,15,183, we broadened the decision tree here and in BOX 3 to include both Pgp and breast cancer resistance protein (BCRP; also known as ABCG2). This is because
similar in vitro methodologies and criteria are used to suggest clinical drug–drug
interaction (DDI) studies for these two transporters. Generally, most P-gp substrates are
organic cations or neutral molecules, relatively hydrophobic, and have a range of
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molecular masses (200 daltons to greater than 1,000 daltons). BCRP substrates tend to
overlap with P-gp but also include acids or drug conjugates that are not good substrates
for P-gp. A new molecular entity (NME) is considered to be a potential P-gp or BCRP
substrate if the efflux ratio — basal to apical (B-A) to apical to basal (A–B) — is ≥ 2 in
an epithelial cell system that expresses one or both transporters (see footnote and (a) in
the figure). A net flux ratio cut-off higher than 2 or a relative ratio to positive controls
may be used to avoid false positives if a ratio of 2 is deemed non-discriminative as
supported by prior experience with the cell system used. Additional corroboration that an
NME may be a P-gp or BCRP substrate can be achieved with the use of inhibitors;
information especially valuable if non-transfected cells are not included as controls for
endogenous transport activity. Reduction of the flux ratio by the P-gp (or BCRP)
inhibitors should be greater than 50% (see (b) in the figure). If the flux ratio is not
reduced by P-gp (or BCRP) inhibitors, then other efflux transporters may be responsible
for the observed net flux (see (d) in the figure).
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The conclusions from in vitro efflux studies are dependent on the cell line used. For
example, for cells heterologously expressing P-gp or BCRP (for example, MDCK or
LLC-PK1), in which expression of the transporters can be high, the efflux ratio would be
expected to be much higher than 2 for strong substrates. A classification of relevant
substrates versus non-substrates will depend on the assay system. Validation studies of in
vitro assay systems using known weak and strong substrates and, where possible,
correlations with in vivo model systems, should be established. Meaningful efflux ratios
are dependent on the transporter expression; thus, results should be related to a reference
compound. In cell lines such as Caco-2, which express multiple uptake and efflux
transporters, reduction of efflux in the presence of an inhibitor may support efflux by Pgp and/or BCRP, depending on the selectivity of the inhibitor used (for example,
cyclosporine inhibits multiple transporters).
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If in vitro experiments suggest that the NME is a P-gp and/or BCRP substrate (see (c) in
the figure), preclinical and clinical information should be assessed to determine whether
a clinical in vivo DDI study is warranted. In particular, the relative contribution of the
transporter-mediated pathway to the overall clearance of the drug is the primary
determinant of whether an inhibitor will have a major effect on the disposition of the
NME. For example, the pharmacokinetics of an NME that has high solubility, high
permeability and/or is highly metabolized are less likely to be affected by a coadministered drug that is a P-gp inhibitor15,173,174. Therefore, an in vivo interaction
study may not be needed. By contrast, an NME that has poor solubility, limited
permeability and is metabolically stable (eliminated primarily as the parent compound) is
more likely to demonstrate a pharmacokinetic change in the presence of an inhibitor. The
possible clinical consequence of such an interaction needs to be assessed based on careful
evaluation of available exposure–response data186,187. The recommended clinical study
with a known P-gp inhibitor should consider the therapeutic use of the NME; however,
cyclosporine is a reasonable choice, as it is known to inhibit P-gp in vivo. As noted
previously, because cyclosporine inhibits multiple transporters, care must be taken in the
design and interpretation of DDI studies in which it is used as an inhibitor.
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This figure shows a decision tree for P-gp and a similar tree could be used for BCRP.
Although flux systems have traditionally been used to determine whether an NME is a
substrate of P-gp or BCRP, inside-out vesicles expressing P-gp or BCRP, or transfected
cell monolayers grown on solid support with appropriate controls (for example, inhibitors
and positive controls) as described in Section 2, also can be used.

Box 3 | Decision trees for P-glycoprotein or BCRP inhibitor interactions
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A new molecular entity (NME) is considered to be a potential P-glycoprotein (P-gp; also
known as MDR1, ABCB1) and/or breast cancer resistance protein (BCRP; also known as
ABCG2) inhibitor if the net flux ratio of a P-gp (or BCRP) probe substrate is decreased
in the presence of the NME using a bi-directional transport assay (see footnote 1 below).
Generally, the potency of inhibition is reported only as an IC50 value, which is
dependent on the test system used. There are several practical challenges in evaluating
whether NMEs that inhibit efflux transporters in vitro are also inhibitors in vivo. Orally
administered drugs that are classified as in vitro efflux inhibitors provide the dual
challenge of considering both intestinal efflux inhibition, in which intestinal drug
concentrations will be the highest, and tissue efflux inhibition, in which circulating
concentrations will be more relevant. Zhang et al.15 proposed that drugs exhibiting an
[I]1/IC50 ≥ 0.1 or [I]2/IC50 ≥10 should be evaluated to determine whether inhibition
occurs in vivo. In that publication, [I]1 is the mean NME steady-state total Cmax at the
highest clinical dose, and [I]2 is the theoretical maximal gastrointestinal NME
concentration after oral administration calculated as the highest clinical dose (mg) in a
volume of 250 ml15. The [I]1/IC50 ≥ 0.1 calculation is familiar to those working on
metabolic inhibition, as this approach has been used for many years.
In this paper, to be consistent with decision trees for other transporters (for example,
organic cation transporter 2 (OCT2) and organic anion transporting polypeptide (OATP))
and the notion that unbound drug is the pharmacologically active species, mean steadystate Cmax values for unbound drug following administration of the highest proposed
clinical dose is used for [I]1 in the decision tree (see footnote 2 for further discussion).
Using this approach, a drug (molecular mass of 500 daltons) with an in vitro IC50 value
of 10 µM will exceed an [I]1/IC50 value > 0.1 at an unbound Cmax > 1 µM (assumes
fraction unbound (fu) = 0.1 and Cmax = 10 µM). This suggests that there is limited drug
interaction potential with P-gp or BCRP. By contrast, for the same drug, an [I]2/IC50
value > 10 will be exceeded at a dose of approximately 12 mg or greater. Thus, a drug
with an inhibition potency of approximately 10 µM or less in vitro is likely to exceed
[I]2/IC50 value > 10 as many drugs require oral doses greater than 12 mg.
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If an NME meets either [I]1/IC50 ≥ 0.1 (for example, IC50 is ≤ 10-fold the unbound
Cmax value) or [I]2/IC50 ≥ 10, an in vivo drug interaction study with digoxin is
recommended. Digoxin is a unique drug (see footnote 3), and may not be the best
reference for decisions regarding interaction studies with other P-gp substrate drugs.
Fenner et al.188 analysed drug interactions with digoxin and suggested that interactions
of digoxin with P-gp inhibitors were limited (for example, most inhibitors caused < 2fold changes in plasma concentrations of digoxin). However, owing to its narrow
therapeutic index, interactions that alter the digoxin AUC > 1.25-fold are clinically
important for digoxin. Therefore, the interpretation of the significance of P-gp for drug–
drug interactions should not be over-extrapolated based on the importance for digoxin
safety, as most other drugs have a much larger therapeutic index. In addition, if the NME
inhibits a cytochrome P450 enzyme as well as P-gp, selection of a drug that is a dual
substrate of cytochrome P450 and P-gp may be deemed appropriate. If the NME is a pure
P-gp inhibitor, other than for clarifying a digoxin dose adjustment requirement, no drug–
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drug interaction studies may be indicated depending on the therapeutic area of the NME
and its drug labeling considerations.
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For an NME that is a BCRP inhibitor, possible candidate probe substrates include
sulphasalazine189, rosuvastatin190, pitavastatin41, ciprofloxacin47 and
dipyridamole191. However, many of these remain to be tested as selective BCRP probe
substrates in clinical studies.
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Note 1: A unidirectional assay based on the probe substrate can also be considered188.
Inside-out vesicles expressing P-gp or BCRP, or transfected cell monolayers grown on
solid support with appropriate controls (for example, inhibitors and positive controls, as
described in Section 2), can also be used for inhibition assays. Note 2: If fu cannot be
accurately determined owing to high protein binding, then assume fu = 0.01, to err on the
conservative side. Alternatively, unbound portal vein concentrations may be used and
might be more applicable to liver uptake192,193. Note 3: Digoxin has an absolute
bioavailability of approximately 70% from immediate release tablets. By contrast, the
absolute bioavailability from a liquid-filled formulation (for example, Lanoxicaps) is
approximately 90%. Therefore, consideration should also be given to the dosage form of
digoxin used in an interaction study. In addition, digoxin may be a substrate for other
transporters15,92,188,194. Hence, caution is advised when extrapolating results from
digoxin to other P-gp substrates.

Box 4 | Decision trees for OCT or OAT substrate interactions
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Generally, most organic cation transporter (OCT) and organic anion transporter (OAT)
substrates are small organic ions (less than 400 daltons) that are relatively hydrophilic.
OCT substrates are typically cations and OAT substrates anions. Of note, OAT3 can also
transport weakly basic compounds such as cimetidine and sitagliptin (Januvia; Merck).
The key clinical renal transporters in the basolateral membrane of the proximal tubule are
OCT2, OAT1 and OAT3. Transporters in the apical membrane of the proximal tubule
that are important, but not a focus of this manuscript, include the multidrug and toxin
extrusion transporters (MATE1 and MATE2-K) and the organic anion transporter
(OAT4), as well as some ATP-binding cassette transporters (for example, MRP2 and
MRP4).
In evaluating whether a new molecular entity (NME) is an OCT or OAT substrate, the
first step to consider is whether the renal clearance (CLr) of the NME is an important
determinant of the total clearance (CLTotal). That is, if CLr ≥ 0.5 × CLTotal (0.5 was
selected because 50% was considered to represent a substantial and clinically important
percentage of the CLTotal). When CLr is a substantial component of CLTotal (or when
the fraction of CLr to CLTotal cannot be estimated because oral bioavailability cannot be
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determined), the second condition to establish is whether renal clearance involves
secretion. That is, if CLr > 1.5 fraction unbound (fu) × glomerular filtration rate (GFR).
If fu cannot be accurately determined, for example, plasma protein binding is greater than
99.9%, or is not known, then assume fu = 0.01, to err on the conservative side. Greater
than 1.5 implies that a substantial fraction of the CLr is due to renal tubular secretion.
If both conditions are met, that is, CLr ≥ 0.5 CLTotal and CLr > 1.5 fu × GFR, then in
vitro uptake into a recombinant cell line expressing renal transporters should be
conducted. These assays should include control cells without recombinant transporters, or
transfected cells with known OCT or OAT inhibitors, or both. To determine whether an
NME is a substrate of an OCT or OAT (or OATP as discussed in BOX 6), the ratio of
NME uptake in the transporter-expressing cells versus the control (or empty vector) cells
should be statistically greater than 1 (see footnote). Michaelis–Menten studies can be
used in the transfected cells to determine the kinetic parameters of the NME.
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For confirmed in vitro substrates of OCT2 or OAT1/3, a clinical drug–drug interaction
(DDI) study could be performed with cimetidine as an inhibitor of organic cation
transport, or probenecid as a broad non-specific OAT inhibitor. Cimetidine and
probenecid are model inhibitors; however, these drugs may not be prescribed commonly.
Therefore, sponsors should consider other more clinically relevant renal transporter
inhibitors, if available, for use in DDI studies. Examples of labels that describe DDIs
mediated by OCTs or OATs include metformin, pramipexole and varenicline.
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The ratio of NME uptake in the cells expressing the transporter versus the control (or
empty vector) cells should be statistically greater than 1. No agreement was reached by
the International Transporter Consortium regarding the magnitude of the ratio. However,
it is important that uptake into the transfected cells be significantly greater than
background in a control cell line and be inhibited by a known inhibitor of the transporter.
A positive control should be included. ‡If the CLr/CLTotal is unknown, go to ‘Yes’.

Box 5 | Decision trees for OCT or OAT inhibitor interactions
Evaluation of organic cation transporter (OCT) or organic anion transporter (OAT)
inhibitors requires determination of an IC50 value in an in vitro study. If the IC50 value
is ≤ 10-fold the unbound Cmax value in cells expressing OCT2 (or OAT1/3), a clinical
drug–drug interaction (DDI) study is recommended. Ten-fold was selected to err on the
conservative side and to be consistent with the P-glycoprotein (P-gp; also known as
MDR1, ABCB1) and breast cancer resistance protein (BCRP; also known as ABCG2)
decision trees. For inhibitors of OCT2, the new molecular entity (NME) can be clinically
evaluated for its potential to inhibit the renal clearance of metformin, a commonly used
Nat Rev Drug Discov. Author manuscript; available in PMC 2012 April 13.
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anti-diabetic drug. However, OCT2 inhibitors may also be multidrug and toxin extrusion
transporter (MATE) inhibitors, and clinical inhibition interactions with metformin may
involve MATE1 or MATE2-K in addition to, or even instead of, OCT2. Therefore, some
caution in the interpretation of in vivo inhibition studies for OCT2 should be exercised.
For OAT1 and OAT3, several potential substrates may be used as ‘victim’ drugs (see
footnote). Some inhibitors of OAT1/3 may also inhibit apical transporters (for example,
ATP-binding cassette transporters); therefore, clinical inhibition data should be
interpreted cautiously.
Selection of an appropriate probe substrate victim drug for the clinical DDI study should
be based upon therapeutic considerations; for example, a victim drug should be selected
that is likely to be co-administered with the NME in a therapeutic setting. Other
considerations should include the therapeutic window of the victim drug and the
maximum effect that would be expected if the secretory clearance of the victim drug was
totally inhibited.

NIH-PA Author Manuscript

For NMEs that are OAT inhibitors, multiple candidate probe substrates could be used in
clinical DDI studies, including zidovudine, lamivudine, zalcitabine, acyclovir,
ciprofloxacin, tenofovir and methotrexate. Some of these substrates may be transported
by multiple transporters. For example, some data suggest that methotrexate renal
elimination may be affected by co-administration of non-steroidal anti-inflammatory
drugs; however, the mechanisms may include other transporters in addition to
OATs195,196. MPP+, 1-methyl-4-phenylpyridinium; OS, oestrone-3-sulphate; PAH,
para-aminohippuric acid.

Box 6 | Decision trees for OATP interactions
organic anion transporting polypeptide (oATP) substrates
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Generally, investigations involving OATPs are focused on the OATP1B family in the
liver. Most OATP1B substrates are large (350–1,000 daltons) organic anions that are
relatively hydrophilic. In addition to parent drugs, a number of Phase II drug conjugates
are OATP1B substrates. For the identification of substrates, heterologous expression
systems including OATP1B1, OATP1B3 and possibly other hepatic OATPs such as
OATP2B1, should be considered. Criteria for establishing whether an NME is an in vitro
substrate of an OATP are discussed in the footnote of BOX 4. If a new molecular entity
(NME) is a substrate of an OATP, then a detailed assessment of non-clinical (for
instance, permeability, metabolism, tissue-to-plasma ratio in liver and other organs) and
clinical data (for instance, dose linearity) should be completed to determine whether a
human pharmacokinetic study is warranted (a).
If a clinical study is necessary, the NME could be given together with a single dose of an
OATP inhibitor such as rifampicin or cyclosporine, as both are broad OATP inhibitors.
However, some care should be taken in the interpretation of the clinical data with respect
to the interaction because these agents can affect many other transporters as well as
absorption, distribution, metabolism and excretion processes. In addition, the
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pharmacokinetics of the NME could be studied in individuals with OATP1B1 single
nucleotide polymorphisms (SNPs) associated with lower OATP activity (as outlined in
Section 1). Functional SNPs in OATP1B3 have been described197, and appear to be
associated with alterations in bilirubin levels198; however, to date, no phenotypic
consequence related to pharmacokinetics has been observed. Therefore, at this time,
clinical studies in individuals with OATP1B3 SNPs are not recommended.
oATP inhibitors
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To assess the potential of an NME to inhibit OATPs, the uptake of a prototypical
substrate such as oestradiol-17-β- glucuronide, a statin or bromosulphophthalein in a
heterologous expression system for OATP1B1 or OAT1B3, should be measured in the
presence of the NME, and the IC50 value of the NME should be determined (b). A
known inhibitor such as rifampicin or cyclosporine should be included as a positive
control127,199. The predicted or actual plasma concentration in vivo should be
considered as a starting point for interpreting the observed IC50 value. If the IC50 value
is ≤ 10 times the unbound Cmax (for example, unbound Cmax/IC50 ≥ 0.1 or [I]/IC50 ≥
0.1), then the NME may be an in vivo OATP inhibitor. If this criterion is met, it is
recommended that an in vitro–in vivo extrapolation approach (R value) be
completed192,193, which takes the maximal unbound drug concentration at the inlet of
the liver (Iin, max) into account (see figure (b) and BOX 7). If the extrapolation suggests
a > 2-fold change in exposure, consider proceeding to a clinical drug–drug interaction
(DDI) study using atorvastatin, pravastatin, pitavastatin or rosuvastatin as OATP1B1 and
OATP1B3 non-selective in vivo probe substrates192,193. Note that calculation of an R
value is only one method of many that are available for extrapolation. In vitro
confirmation that the NME inhibits the uptake of the statin, which is proposed as an in
vivo probe substrate, should be obtained before proceeding to the clinical DDI study.
To estimate the magnitude of the expected clinical effect of the NME on the statin,
calibration of the R value should be performed using OATP inhibitors such as rifampicin
or cyclosporine as positive controls127,199. It has been noted that telmisartan may prove
to be useful as an OATP1B3 selective substrate; thus telmisartan can be considered if a
potential drug interaction specific to OATP1B3 needs to be assessed in vivo98. Examples
of how the R value is calculated and used are described in BOX 7.
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*Low permeability needs to be defined by each laboratory based on standards, such as
atenolol (a Biopharmaceutics Classification System reference drug). A general guide
would be 1 × 10−6 cm per sec (10 nm per sec) or lower is classed as low permeability. ‡R
value is defined as 1+(fu × Iin, max/IC50), in which Iin, max is the estimated maximum
inhibitor concentration at the inlet to the liver and is equal to: Imax + (Fa × Dose × ka/
Qh). Imax is the maximum systemic plasma concentration of the inhibitor; Fa is the
fraction of the dose of the inhibitor, Dose, which is absorbed; ka is the absorption rate
constant of the inhibitor; and Qh is the hepatic blood flow (for example, 1,500 ml per
min).
Box 7 | OATP1B1 decision analysis: case studies
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Current information suggests that HIV protease inhibitors are organic anion transporting
polypeptide (OATP) inhibitors. Lopinavir is administered at high doses (400 mg)
yielding total Cmax values of approximately 15–20 µM, representing approximately
0.23–0.3 µM free drug (fraction unbound (fu) = 0.015)200. In vitro inhibition assays
demonstrated that lopinavir inhibited OATP1B1 with an IC50 value of 0.1 µM. As the
IC50 value is less than ten times the unbound Cmax, completion of an extrapolation is
recommended for OATP1B1 (see BOX 6 for OATP inhibition decision tree). An R value
for lopinavir of 9.2 is calculated201 using the following equation and parameters: R = 1+
(fu × Iin, max/IC50); Iin, max = 54.8 µM200 (see BOX 6 footnote for further explanation
of calculation of the R value and of definition of Iin, max); the fraction of drug absorbed,
Fa = 1.0; the absorption rate constant, ka = 0.03 per min202; hepatic blood flow, Qh =
1,500 ml per min. These estimates assume that the fraction of the substrate transported by
OATP1B1 is 100%. However, the magnitude of clinical interaction will be attenuated if
the fraction transported by a single pathway is less than 100% (for example, a second
route of transport). For rosuvastatin, the contribution of OATP1B1 to the hepatic uptake
is estimated to be 54%. As shown in the drug label, the clinical drug–drug interaction
(DDI) with lopinavir and ritonavir combination (400 mg and 100 mg) twice a day for 10
days yields a two fold change in AUC and five fold change in Cmax of rosuvastatin. This
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is probably due to lopinavir inhibiting OATP1B1 (ritonavir’s effect on OATP1B1 is
discussed below).
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A similar analysis can be completed for two other HIV protease inhibitors: for ritonavir
— 100 mg dose; fu = 0.02198; Cmax = 1.73 µM203; Iin, max = 4.51 µM, (using Fa =
1.0, Qh = 1,500 ml per min and ka = 0.03 per min202) — the unbound concentration is <
1 µM, when used as a boosting agent only. However, the IC50 value (0.3 µM) is less
than ten times the unbound ritonavir concentration (0.05 µM). The extrapolation yields
an R value of 1.3, suggesting that the drug interaction potential of ritonavir with OATP
substrates is minimal based solely on plasma concentrations, and that a DDI study to
evaluate the clinical significance of OATP inhibition is not needed.
For amprenavir (600 mg dose; fu = 0.1; Cmax = 12.0 µM; Iin, max = 35.8 µM)203,
unbound concentrations are > 1 µM and the IC50 value (5.5 µM) for OATP1B1 is five
fold higher than the unbound concentration (1.2 µM). Extrapolation provides an R value
of 1.7, suggesting that a DDI study may not be required. Indeed, the lack of an interaction
between amprenavir (when administered as fosamprenavir) and rosuvastatin was
confirmed in a clinical study201. Furthermore, in this study, ritonavir was present as a
boosting agent, suggesting that this low-dose ritonavir does not inhibit OATP in vivo.
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Absorption,
Distribution,
Metabolism and
Excretion (ADME)

The acronym ADMe describes the factors that determine the
overall exposure to an administered drug. Absorption describes
uptake from the site of administration. Although usually
referring to oral route, other routes can apply, for example,
subcutaneous or buccal. As drug levels are typically measured
systemically, oral absorption can be a function of movement
across the mucosal surface of the intestinal tract, through the
liver and into the systemic circulation via the vena cava.
Distribution describes the extent of partitioning into tissues.
Metabolism refers to a chemical change usually catalysed by
enzymes such as the cytochrome P450s. The drug and its
metabolites are excreted or eliminated usually by the kidney (in
urine) or from the liver (via bile) or intestines into the faeces

Blood brain barrier
(BBB)

The BBB consists of endothelial cells connected by tight
junctions. The endothelial cells, which are surrounded by
astrocytes, separate the circulating blood and the brain interstitial
space. The role of the BBB is to protect the central nervous
system by restricting and preventing the entry of toxic
substances including drug molecules and bacteria into the brain.
Included in this protective barrier are transporters such as P-gp

Drug Clearance

The clearance of a drug is defined as the proportionality constant
between rate of elimination and plasma concentration. The total
clearance (CLTotal) reflects the rate of removal from the systemic
circulation (the site of monitoring concentrations). Clearance by
an organ can also be defined (e.g. renal clearance (CLr) via
excretion and hepatic clearance (CLh) via metabolism and/or
biliary excretion). Renal clearance of a drug is determined by
glomerular filtration and tubular secretion and reabsorption, both
of which may be transporter-mediated.
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Drug-drug
interaction (DDI)

Concomitant administration of multiple drugs can result in
altered levels of the drugs, compared to administration of the
drugs alone. DDI can result in higher (inhibition) or lower
(induction) levels of the drug. For example, if drug A
(“perpetrator” drug) inhibits a membrane transporter that drug B
(“victim” drug) uses to enter into the cell, administration of drug
A can lower the level of drug B in the cell and also potentially
increase the level of drug B in the systemic circulation

Drug-metabolizing
enzymes (DMEs)

These are enzymes responsible for chemical modification of
drugs usually to increase rate of elimination. The activity of
these enzymes can be altered through inhibition or induction (upregulation) thus affecting the rate of metabolism

Fraction unbound, fu

This fraction represents the ratio of unbound drug concentration
to total drug concentration in the plasma. The fu is determined
by the affinity of drugs to the binding proteins (e.g., albumin and
α1-acid glycoprotein) in plasma and the total number of binding
sites on the proteins

IC50 and Ki

IC50 value, as used in this paper, is the concentration of an
inhibitor needed to inhibit one-half of the transport rate of the
substrate measured in the absence of the inhibitor. The IC50 of a
drug is determined by a concentration - transport rate curve. To
determine the IC50 value of an inhibitor of a drug transporter, the
effect of increasing concentrations of the inhibitor on the
transport rate of a substrate is determined.

Ki

Ki is the inhibition constant of the drug inhibitor, and for
competitive inhibition is determined as, Ki = IC50/[1+([s]/Km)],
in which [s] is the concentration of the drug substrate and Km is
the affinity of the drug substrate for the drug transporter.

Membrane
transporters

Membrane-associated proteins that govern the transport of
solutes (e.g., drugs and other xenobiotics) into and out of cells.
Transporters can play a critical role in determining drug
concentrations in the systemic circulation and in cells. The two
major superfamilies of membrane transporters are the ABC
(ATP-binding cassette) and SLC (Solute Carrier) superfamilies

Pharmacodynamics

Pharmacodynamics describe the extent and time course of effects
of drugs on physiologic and pathophysiologic processes. The
relationship between drug concentration and drug effect is
important in determining pharmacodynamics

Pharmacokinetics

Pharmacokinetics describe what the body does to a drug.
Pharmacokinetic parameters result from the ADME properties of
a drug, and provide information about the rates of elimination
and systemic levels of drugs. The functional activity and level of
a drug transporter can determine the amount of drug molecule
transported into or out of specific tissues, which will determine
the level of drugs in that tissue and also the systemic circulation

Substrate or
Inhibitor

A substrate of a drug transporter is translocated across a
membrane by the transporter. An inhibitor of a drug transporter
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can impair the uptake and/or efflux of another drug. Many
inhibitors are not substrates, i.e., are not transported by the
transporter. Substrates can competitively inhibit other substrates
that interact at the same site(s) on the transporter
Unbound inhibitor
concentration [I]

The unbound drug is the pharmacologically active species and is
available for inhibition of transporters. Typically, mean unbound
steady-state Cmax values following administration of the highest
proposed clinical dose is used for [I]1 in the decision tree. Note
that the definition of [I]1 used in this report differs from that
described by Zhang et al. (ref. 15) in the original published Pglycoprotein decision tree. Defining [I] as the unbound steadystate maximum concentration was intentionally done to provide
consistency across the all the decision trees included in this
report
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Figure 1. selected human transport proteins for drugs and endogenous substances
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Transporters in plasma membrane domains of intestinal epithelia, hepatocytes, kidney
proximal tubules and brain capillary endothelial cells are presented. Those coloured in red
indicate that the selected transporters are described in detail in this manuscript. Those
coloured in blue indicate that the transport proteins are of importance but are not described
in this manuscript. a | Intestinal epithelia contain in their apical (luminal) membrane several
uptake transporters including one or more members of the organic anion transporting
polypeptide (OATP) family; peptide transporter 1 (PEPT1; SLC15A1); ileal apical sodium/
bile acid co-transporter (ASBT; SLC10A2); and monocarboxylic acid transporter 1 (MCT1;
SLC16A1). The apical ATP-dependent efflux pumps include multidrug resistance protein 2
(MRP2; ABCC2); breast cancer resistance protein (BCRP; ABCG2); and P-glycoprotein (Pgp; MDR1, ABCB1). The basolateral membrane of intestinal epithelia contains organic
cation transporter 1 (OCT1; SLC22A1); heteromeric organic solute transporter (OSTα–
OSTβ); and MRP3 (ABCC3). b | Human hepatocyte uptake transporters in the basolateral
(sinusoidal) membrane include the sodium/taurocholate co-transporting peptide (NTCP;
SLC10A1); three members of the OATP family (OATP1B1 (SLCO1B1), OATP1B3
(SLCO1B3) and OATP2B1 (SLCO2B1)); organic anion transporter 2 (OAT2; SLC22A7)
and OAT7 (SLC22A9); and OCT1. Efflux pumps in the hepatocyte basolateral membrane
include MRP3, MRP4 (ABCC4) and MRP6 (ABCC6). Apical (canalicular) efflux pumps of
the hepatocyte comprise P-gp; bile-salt export pump (BSEP or SPGP; ABCB11); BCRP
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(ABCG2); and MRP2. In addition, multidrug and toxin extrusion protein 1 (MATE1;
SLC47A1) is located in the apical hepatocyte membrane. c | Kidney proximal tubules
contain in the apical (luminal) membrane OAT4 (SLC22A11); urate transporter 1 (URAT1;
SCL22A12); PEPT1 and PEPT2 (SLC15A2); MRP2 and MRP4; MATE1 and MATE2-K
(SLC47A2); P-gp; organic cation/ergothioneine transporter (OCTN1; SLC22A4); and
organic cation/carnitine transporter (OCTN2; SLC22A5). Basolateral uptake transporters in
proximal tubule epithelia include OATP4C1 (SLCO4C1); OCT2; and OAT1, OAT2 and
OAT3 (SLC22A8). d | Apical (luminal) transport proteins of brain capillary endothelial cells
contributing to the function of the blood–brain barrier include the uptake transporters
OATP1A2 and OATP2B1; and the efflux pumps P-gp, BCRP, MRP4 and MRP5 (ABCC5).
Note that localization of transporters to particular membranes and tissues is sometimes
controversial; therefore, the International Transporter Consortium erred on the conservative
side in only showing the localization of transporters for which good evidence exists.
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Figure 2. Decision tree for computer modelling of transporter proteins
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Ligand-based methods such as pharmacophore and 3D-quantitative structure–activity
relationship modelling (3D-QSAR) will be required when crystal structure templates are not
available or can be used to complement existing homology models. Generally, a highthroughput in vitro assay is used to generate a data set of transporter ligands (substrates or
inhibitors) and their corresponding activity values (Km/Jmax, Ki, or percentage inhibition).
a | Data sets are split into a training set used to construct a model and a test set to validate
the model. b | Criteria for model acceptance depend on its ability to successfully predict
biological activity of test set molecules. c | Acceptable models may be combined to generate
synergistic consensus models. d | To generate homology models with high confidence, the
membrane topology of both the target and scaffold proteins must match. Modelling of
transporters with divergent topology should be attempted with great caution as it is currently
unclear how the arbitrary deletion or insertion of a membrane helix may distort the overall
helical packing of membrane proteins. e | To further increase fidelity, models should be
optimized using molecular dynamics simulations (MDS), preferably embedded in a lipid
bilayer surrounded by an aqueous environment. f | When all criteria are satisfied, homology
models may be used to determine regions of substrate binding or interaction and mapping of
possible permeation pathways. g | Biochemical validation — for example, substituted
cysteine accessibility method (SCAM) — will therefore be needed. TMD, transmembrane
domain.

Nat Rev Drug Discov. Author manuscript; available in PMC 2012 April 13.

Page 42

Table 1

SLC transporters of emerging clinical importance in the absorption and disposition of drugs

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Transporter/
alias (Gene)

Selected substrates

Selected
inhibitors

Organs/cells

Comments

OATP1B1/O
ATP-C,
OATP2, LST1 (SLCO1B1)

Bromosulphophthalein,
oestrone-3-sulphate,
oestradiol-17β-glucuronide,
statins*, repaglinide*,
valsartan, olmesartan*,
bilirubin glucuronide,
bilirubin, bile acids

Saquinavir,
ritonavir*,
lopinavir*,
rifampicin*,
cyclosporine*

Hepatocytes
(sinusoidal)

• Has a role in
disposition and
excretion
• Has clinically relevant
polymorphisms
• Has a role in clinical
drug–drug interactions

OATP1B3/O
ATP-8
(SLCO1B3)

Bromosulphophthalein,
cholecysto kinin 8, statins*,
digoxin, fexofenadine,
telmisartan glucuronide,
telmisartan*, valsartan,
olmesartan, oestradiol-17β-glucuronide, bile acids

Rifampicin*,
cyclosporine*,
ritonavir,
lopinavir*

Hepatocytes
(sinusoidal)

• Has a role in
disposition and
excretion

OAT1
(SLC22A6)

Para-aminohippurate,
adefovir, cidofovir,
zidovudine*, lamivudine*,
zalcitabine*, acyclovir*,
tenofovir*, ciprofloxacin*,
methotrexate*

Probenecid*,
novobiocin

Kidney
proximal
tubule,
placenta

• Has a role in
disposition and
excretion Has a role in
clinical drug–drug
interactions

OAT3
(SLC22A8)

Oestrone-3-sulphate, nonsteroidal anti-inflammatory
drugs, cefaclor, ceftizoxime,
furosemide*, bumetanide*

Probenecid*,
novobiocin

Kidney
proximal
tubule,
choroid
plexus,
blood–brain
barrier

• Has a role in
disposition and
excretion
• Has a role in clinical
drug–drug interactions

OCT2
(SLC22A2)

N-Methylpyridinium,
tetraethylammonium,
metformin*, pindolol,
procainamide, ranitidine
amantadine, amiloride,
oxaliplatin, varenicline*

Cimetidine*,
pilsicainide,
cetirizine*,
testosterone,
quinidine

Kidney
proximal
tubule,
neurons

• Has a role in
disposition and
excretion
• Has clinically relevant
genetic
polymorphisms
• Has a role in clinical
drug–drug interactions

OATP1A2/O
ATP-A
(SLCO1A2)

Oestrone-3-sulphate,
dehydroepiandrosterone
sulphate, fexofenadine*,
bile salts, methotrexate,
bromosulphophthalein,
ouabain, digoxin,
levofloxacin, statins*

Naringin,
ritonavir,
lopinavir,
saquinavir,
rifampicin*

Brain
capillaries
endothelia,
cholangiocyte
s, distal
nephron

• Has role in disposition
and excretion

OATP2B1/O
ATP-B
(SLCO2B1)

Oestrone-3-sulphate,
bromosulphophthalein,
taurocholate, *statins,
fexofenadine, glyburide,
taurocholate

Rifampicin,
cyclosporine*

Hepatocytes
(sinusoidal),
endothelia

• Has a role in
disposition and
excretion
• Has a role in clinical
drug–drug interactions

OCT1
(SLC22A1)

Tetraethylammonium, Nmethylpyridinium,
metformin*, oxaliplatin

Quinine,
quinidine,
disopyramide

Hepatocytes
(sinusoidal),
intestinal
enterocytes

• Has a role in
disposition and
excretion
• Has clinically relevant
genetic
polymorphisms
• Has a role in clinical
drug–drug interactions
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Transporter/
alias (Gene)

Selected substrates

Selected
inhibitors

Organs/cells

Comments

PEPT1
(SLC15A1)

Glycylsarcosine,
cephalexin, cefadroxil,
bestatin, valacyclovir,
enalapril, aminolevulinic
acid, captopril, dipeptides,
tripeptides

Glycyl-proline

Intestinal
enterocytes,
kidney
proximal
tubule

• Has a role in
absorption, disposition
and excretion
• Has a role in clinical
drug–drug interactions

PEPT2
(SLC15A2)

Glycylsarcosine,
cephalexin, cefadroxil,
bestatin, valacyclovir,
enalapril, aminolevulinic
acid, captopril, dipeptides,
tripeptides

Zofenopril,
fosinopril

Kidney
proximal
tubule,
choroid
plexus, lung

• Has a role in excretion
MATE1

(SLC47A1)

Metformin, Nmethylpyridinium,
tetraethylammonium

Quinidine,
cimetidine,
procainamide

Kidney
proximal
tubule, liver
(canalicular
membrane),
skeletal
muscle

• Has a role in
disposition and
excretion
• Has a role in clinical
drug–drug interactions

MATE2-K
(SLC47A2)

Metformin, Nmethylpyridinium,
tetraethylammonium

Cimetidine,
quinidine,
pramipexole

Kidney
proximal
tubule

• Has a role in
disposition and
excretion

*

NIH-PA Author Manuscript

Can potentially be used for in vivo (clinical) studies.
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Table 2

ABC transporters of emerging clinical importance in the absorption and disposition of drugs

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Transporter/alias
(Gene)

Selected substrates

Selected
inhibitors

Organs/cells

MDR1/P-gp, ABCB1 (ABCB1)

Digoxin*,
loperamide*,
berberine, irinotecan,
doxorubicin,
vinblastine,
paclitaxel,
fexofenadine

Cyclosporine*, quinidine*,
tariquidar, verapamil

Intestinal enterocytes,
kidney proximal tubule,
hepatocytes
(canalicular), brain
endothelia

•

Has a role in
absorption,
disposition and
excretion

•

Has a role in
clinical drug–
drug
interactions

Mitoxantrone,
methotrexate,
topotecan, imatinib,
irinotecan, statins*,
sulphate conjugates,
porphyrins

Oestrone-17β-oestradiol, fumitre morgin C

Intestinal enterocytes,
hepatocytes
(canalicular), kidney
proximal tubule, brain
endothelia, placenta,
stem cells, mammary
glands (lactating)

•

Has a role in
absorption,
disposition and
excretion

•

Has clinically
relevant
genetic
polymorphisms

•

Has a role in
clinical drug–
drug
interactions

•

Has a role in
excretion

•

Has clinically
relevant
genetic
polymorphisms

•

Has a role in
clinical drug–
drug
interactions

•

Has a role in
absorption,
disposition and
excretion

•

Has clinically
relevant
Genetic
polymorphisms

•

Has a role in
clinical drug–
drug
interactions

BCRP/MXR (ABCG2)

BSEP/SPGP, cBAT, ABCB11
(ABCB11)

MRP2/ABCC2, cMOAT (ABCC2)

Taurocholic acid,
pravastatin, bile acids

Cyclosporin A, rifampicin,
glibenclamide

Hepatocytes (canalicular)

Hepatocytes
(canalicular), kidney
(proximal tubule,
luminal), enterocytes
(luminal)

Comments

Glutathione and
glucuronide
conjugates,
methotrexate,
etoposide,
mitoxantrone,
valsartan,
olmesartan,
glucuronidated
SN-38

Cyclosporine, delaviridine,
efavirenz, emtricitabine

MRP3/ABCC3 (ABCC3)

Oestradiol-17βglucuronide,
methotrexate,
fexofenadine,
glucuronate
conjugates

Delaviridine, efavirenz, emtricitabine

Hepatocytes (sinusoidal),
intestinal enterocytes
(basolateral)

•

• Has a role in
disposition

MRP4/ABCC4 (ABCC4)

Adefovir, tenofovir,
cyclic AMP,
dehydroepiandrostero
ne sulphate,
methotrexate,
topotecan,

Celecoxib, diclofenac

Kidney proximal tubule
(luminal), choroid
plexus, hepatocytes
(sinusoidal), platelets

•

• Has a role in
disposition and
excretion
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Transporter/alias
(Gene)

Selected substrates

NIH-PA Author Manuscript

Selected
inhibitors

Organs/cells

Verapamil, cyclosporine

Hepatocytes (canalicular)

Comments

furosemide, cyclic
GMP, bile acids plus
glutathione
MDR3/ABCB4 (ABCB4)

Phosphatidylcholine,
paclitaxel, digoxin,
vinblastine

ABC, ATP-binding cassette.
*

Can potentially be used for in vivo (clinical) studies.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Nat Rev Drug Discov. Author manuscript; available in PMC 2012 April 13.

•

Has a role in
disposition

•

Has a role in
clinical drug–
drug
interactions
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Table 3

Selected transporter-mediated clinical drug–drug interactions

NIH-PA Author Manuscript

Implicated transporter*

Interacting drug

Affected drug

Clinical pharmacokinetic impact on affected
drug‡

Organic anion transporting polypeptides

Cyclosporine

Pravastatin

AUC ↑890% and Cmax ↑678%102,204

Cyclosporine

Rosuvastatin

AUC ↑610%205

Cyclosporine

Pitavastatin

AUC ↑ 360% and Cmax ↑560%206

Rifampicin (single dose)

Glyburide

AUC ↑125%207

Rifampicin (single dose)

Bosentan

Ctrough ↑ 500%208

Lopinavir/ritonavir

Bosentan

Day 4: Ctrough ↑ 4,700%208; day 10: Ctrough ↑
400%208

Lopinavir/ritonavir

Rosuvastatin

AUC ↑107% and Cmax ↑365%209

Probenecid

Cidofovir

CLr ↓32%210,211

Probenecid

Furosemide

CLr ↓66%210

Probenecid

Acyclovir

CLr ↓32% and AUC ↑40%210,212

Cimetidine

Metformin

AUC ↑50% and CLr ↓ 27%213,214

Cimetidine

Pindolol

CLr ↓~34%215

Cimetidine

Varenicline

AUC ↑29%216

Cimetidine

Pilsicainide

AUC ↑33%, CLr ↓28%217

Cimetidine

Pilsicainide

CLr ↓41%218

Cimetidine

Dofetilide

CLr ↓33%219

Quinidine

Digoxin

CLr ↓34–48%220,221

Ritonavir

Digoxin

AUC ↑86%222

Dronedarone

Digoxin

AUC ↑157% and Cmax ↑75%223

Ranolazine

Digoxin

AUC ↑60% and Cmax ↑46%224

GF120918

Topotecan

AUC ↑143%225

Organic anion transporters

Organic cation transporters

NIH-PA Author Manuscript

P-glycoprotein

Breast cancer resistance protein
*

Implicated transporter refers to the likely transporter; however, because the studies are carried out in vivo it is not possible to assign specific
transporters to the drug–drug interaction.
‡

Percent change refers to the difference between the area under the curve (AUC), or Cmax, in the presence and the absence of the inhibitor

NIH-PA Author Manuscript

(interacting drug) normalized to the AUC in the absence of the inhibitor. For clearance values (CLr), the values are normalized for the absence of
the inhibitor. Ctrough is the minimum drug concentration observed after administration of a dose of the drug and the concentration prior to the
administration of a subsequent dose.
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